An Evaluation of Fixed-Dose Combinations (FDC’s) for Treatment of type 2 Diabetes Mellitus

Abstract

Today, when we look at diabetes care management as a comprehensive approach to improve quality of life health outcomes and reduce the economic burden of medical care. Evidence-based clinical guidelines for Type 2 DM recommends fixed dose combination (FDC) based Pharmacotherapy involving early utilization of multiple drug agents as a single FDC’s. This study examines the rationality of diverse FDCs used for Diabetes Mellitus and to find out the irrational FDCs currently available in Indian drug market. Material and Methods: - Analytical Study Design. Data aboutvarious FDC’s used for Diabetes Mellitus, which are authorized in Indian marketplace was gathered from Present Index of Medical Specialties (CIMS) and Monthly Index of Medical Specialties (MIMS) and their rationality was analysed using a pretested device instrument primarily based on FDCs listed in WHO essential listing of drugs and National List of Essential Medicines (NLEM), others based totally on their pharmacodynamic properties, Pharmacokinetic parameters and significant drug interactions taking place due to API (Active pharmaceutical substances) contained within the product. Result: A general of 18 mixtures were analysed, amongst those eleven combos were irrational. Conclusion: Predominantly some irrational FDCs are being circulated within the Indian market therefore utmost importance has to be given before prescribing FDC’s to the patients inorderto avoid unnecessary Adverse Drug Reactions (ADR). A wider reform is needed in the government regulatory architecture to inspectof advertised FDCs available in the market. The ignorance and negligence among medical practitioners and pharmacists with regard to the irrational FDC’s has to be addressed immediately.